Intrapartum, LLC was founded by a retired Mayo Clinic OBGYN and a Johnson & Johnson executive, The company offers a unique disruptive technology that promises to dramatically reduce the occurrence of births by Caesarean section (now about 33% of U.S. births). Intrapartum believes that clinicians and insurers will embrace this technology.
At a current rate of nearly 133 million births in the world annually (4 million births in the U.S.), the market for Intrapartum's delivery measurement system is huge. The system includes durable and single-use consumable components. Intrapartum has evaluated multiple methods to measure prenatal and delivery metrics, and a proof-of-concept has been completed.
$2.5 million will take Intrapartum to the completion of product development and FDA approval over 18 months. An additional $2.5 million will take Intrapartum into production and distribution.
Intrapartum now has 8 issued patents (4 pending) that completely capture the IP.